275 related articles for article (PubMed ID: 33586348)
21. Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC.
Amato KR; Wang S; Hastings AK; Youngblood VM; Santapuram PR; Chen H; Cates JM; Colvin DC; Ye F; Brantley-Sieders DM; Cook RS; Tan L; Gray NS; Chen J
J Clin Invest; 2014 May; 124(5):2037-49. PubMed ID: 24713656
[TBL] [Abstract][Full Text] [Related]
22. miR-141 is a key regulator of renal cell carcinoma proliferation and metastasis by controlling EphA2 expression.
Chen X; Wang X; Ruan A; Han W; Zhao Y; Lu X; Xiao P; Shi H; Wang R; Chen L; Chen S; Du Q; Yang H; Zhang X
Clin Cancer Res; 2014 May; 20(10):2617-30. PubMed ID: 24647573
[TBL] [Abstract][Full Text] [Related]
23. YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer - Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer.
Li F; Xu Y; Liu B; Singh PK; Zhao W; Jin J; Han G; Scott AW; Dong X; Huo L; Ma L; Pizzi MP; Wang Y; Li Y; Harada K; Xie M; Skinner HD; Ding S; Wang L; Krishnan S; Johnson RL; Song S; Ajani JA
Clin Cancer Res; 2019 Apr; 25(7):2264-2277. PubMed ID: 30563933
[TBL] [Abstract][Full Text] [Related]
24. C-terminal binding protein-2 promotes cell proliferation and migration in breast cancer via suppression of p16INK4A.
Yang X; Sun Y; Li H; Shao Y; Zhao D; Yu W; Fu J
Oncotarget; 2017 Apr; 8(16):26154-26168. PubMed ID: 28412731
[TBL] [Abstract][Full Text] [Related]
25. EphA2 super-enhancer promotes tumor progression by recruiting FOSL2 and TCF7L2 to activate the target gene EphA2.
Cui S; Wu Q; Liu M; Su M; Liu S; Shao L; Han X; He H
Cell Death Dis; 2021 Mar; 12(3):264. PubMed ID: 33712565
[TBL] [Abstract][Full Text] [Related]
26. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.
Miao B; Ji Z; Tan L; Taylor M; Zhang J; Choi HG; Frederick DT; Kumar R; Wargo JA; Flaherty KT; Gray NS; Tsao H
Cancer Discov; 2015 Mar; 5(3):274-87. PubMed ID: 25542448
[TBL] [Abstract][Full Text] [Related]
27. Claudin-4 controls the receptor tyrosine kinase EphA2 pro-oncogenic switch through β-catenin.
Shang X; Lin X; Howell SB
Cell Commun Signal; 2014 Oct; 12():59. PubMed ID: 25344320
[TBL] [Abstract][Full Text] [Related]
28. [Over-expression of miR-141 inhibits the proliferation, invasion and migration of hepatocellular carcinoma MHCC-97H cells].
Yao B; Xue Y; Liu Z; Xu M; Tu K; Wang J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Aug; 32(8):1083-7. PubMed ID: 27412940
[TBL] [Abstract][Full Text] [Related]
29. EphA2 Is a Potential Player of Malignant Cellular Behavior in Non-Metastatic Renal Cell Carcinoma Cells but Not in Metastatic Renal Cell Carcinoma Cells.
Cho MC; Cho SY; Yoon CY; Lee SB; Kwak C; Kim HH; Jeong H
PLoS One; 2015; 10(7):e0130975. PubMed ID: 26177500
[TBL] [Abstract][Full Text] [Related]
30. EphA2 affects the sensitivity of oxaliplatin by inducing EMT in oxaliplatin-resistant gastric cancer cells.
Wen Q; Chen Z; Chen Z; Chen J; Wang R; Huang C; Yuan W
Oncotarget; 2017 Jul; 8(29):47998-48011. PubMed ID: 28624791
[TBL] [Abstract][Full Text] [Related]
31. Emerging strategies for EphA2 receptor targeting for cancer therapeutics.
Tandon M; Vemula SV; Mittal SK
Expert Opin Ther Targets; 2011 Jan; 15(1):31-51. PubMed ID: 21142802
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of UBE2N-dependent CDK6 protein degradation by miR-934 promotes human bladder cancer cell growth.
Yan H; Ren S; Lin Q; Yu Y; Chen C; Hua X; Jin H; Lu Y; Zhang H; Xie Q; Huang C; Huang H
FASEB J; 2019 Nov; 33(11):12112-12123. PubMed ID: 31373842
[TBL] [Abstract][Full Text] [Related]
33. EphA2-dependent molecular targeting therapy for malignant tumors.
Biao-xue R; Xi-guang C; Shuan-ying Y; Wei L; Zong-juan M
Curr Cancer Drug Targets; 2011 Nov; 11(9):1082-97. PubMed ID: 21933105
[TBL] [Abstract][Full Text] [Related]
34. Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer.
De Robertis M; Loiacono L; Fusilli C; Poeta ML; Mazza T; Sanchez M; Marchionni L; Signori E; Lamorte G; Vescovi AL; Garcia-Foncillas J; Fazio VM
Clin Cancer Res; 2017 Jan; 23(1):159-170. PubMed ID: 27401248
[TBL] [Abstract][Full Text] [Related]
35. Activation of mammalian target of rapamycin complex 1 (mTORC1) and Raf/Pyk2 by growth factor-mediated Eph receptor 2 (EphA2) is required for cholangiocarcinoma growth and metastasis.
Cui XD; Lee MJ; Kim JH; Hao PP; Liu L; Yu GR; Kim DG
Hepatology; 2013 Jun; 57(6):2248-60. PubMed ID: 23315987
[TBL] [Abstract][Full Text] [Related]
36. EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer.
Dunne PD; Dasgupta S; Blayney JK; McArt DG; Redmond KL; Weir JA; Bradley CA; Sasazuki T; Shirasawa S; Wang T; Srivastava S; Ong CW; Arthur K; Salto-Tellez M; Wilson RH; Johnston PG; Van Schaeybroeck S
Clin Cancer Res; 2016 Jan; 22(1):230-242. PubMed ID: 26283684
[TBL] [Abstract][Full Text] [Related]
37. The receptor tyrosine kinase EphA2 is a direct target gene of hypermethylated in cancer 1 (HIC1).
Foveau B; Boulay G; Pinte S; Van Rechem C; Rood BR; Leprince D
J Biol Chem; 2012 Feb; 287(8):5366-78. PubMed ID: 22184117
[TBL] [Abstract][Full Text] [Related]
38. A-kinase-interacting protein 1 promotes EMT and metastasis via PI3K/Akt/IKKβ pathway in cervical cancer.
Zhang X; Liu S; Zhu Y
Cell Biochem Funct; 2020 Aug; 38(6):782-791. PubMed ID: 32401379
[TBL] [Abstract][Full Text] [Related]
39. EphA2 as a target for ovarian cancer therapy.
Landen CN; Kinch MS; Sood AK
Expert Opin Ther Targets; 2005 Dec; 9(6):1179-87. PubMed ID: 16300469
[TBL] [Abstract][Full Text] [Related]
40. Low expression of NCOA5 predicts poor prognosis in human cervical cancer and promotes proliferation, migration, and invasion of cervical cancer cell lines by regulating notch3 signaling pathway.
Liang Y; Zhang T; Shi M; Zhang S; Guo Y; Gao J; Yang X
J Cell Biochem; 2019 Apr; 120(4):6237-6249. PubMed ID: 30335900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
